runs a telehealth model that may involve semaglutide, so this review looks at the compound itself, the routes it reaches patients through, and the biology that governs its effect
161 However, these problems have not been shown to have a clear causal relationship with GLP-1RA in the general population, and there is a lack of data specific to the MASLD population, especially in individuals without co-existing T2DM
Some healthcare providers may prescribe both off-label in select cases, but this requires careful patient selection, comprehensive cardiovascular screening, and close monitoring for additive side effects including increased heart rate, blood pressure changes, and gastrointestinal symptoms
Three-Way Comparison: Retatrutide vs Tirzepatide vs Semaglutide Adding semaglutide provides context for the full generational progression of GLP-1 based therapies